Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, announced today that it has acquired an exclusive world-wide license from Eli Lilly and Company (Lilly) to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human ...

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

(NIH/National Center for Research Resources) The National Institutes of Health and Eli Lilly and Company will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of sophisticated disease-relevant testing systems, NIH announced today. Comprehensive knowledge of the biological profiles of ...

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) ("Amylin") and Eli Lilly and Company (NYSE: LLY) ("Lilly") today announced an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the companies. As part of the agreement, the parties will transition full responsibility for the worldwide development and commercialization of ...

The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly and Company. The funding will support IDRI's continued early phase drug discovery research, which focuses on the identification of effective new therapies ...

Eli Lilly and Company (NYSE: LLY) announced that it is providing more than $4 million in additional funding to the Infectious Disease Research Institute. The funding will allow IDRI to continue its early phase drug discovery efforts focused on identifying new and better therapies in the fight against tuberculosis, including ...

Albany, NY (November 7, 2011) AMRI (NASDAQ: AMRI) announced today that, as part of a new collaboration agreement with Eli Lilly and Company, it anticipates hiring more than 40 synthetic chemists by the third quarter of 2012 to support Lilly's drug discovery programs. The chemists will work onsite at ...

(AMRI) AMRI (NASDAQ: AMRI) announced today that, as part of a new collaboration agreement with Eli Lilly and Company, it anticipates hiring more than 40 synthetic chemists by the third quarter of 2012 to support Lilly's drug discovery programs.

Eli Lilly and Company today announced financial results for the third quarter of 2011.

U.S. drug regulators, FDA have approved Eli Lilly's drug Cialis to treat enlargement of the prostate on Thursday. This expands the usage of the popular impotence medicine.